

JUL 02 2007

Our Docket No.: 102912-200
Page 1 of 3

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:	Lorenz Poellinger Teresa Pereira Jorge Rums	Docket:	3743/49008
Serial No.:	09/922,958	Art Unit:	1642
Filed:	August 7, 2001	Examiner:	Brandon J. Fetterolf
Assignee:	AngioGenetics Sweden AB	Conf. No.:	9818
Customer No.:	27267	Our Reference: 102912-200	
Title:	MECHANISM OF CONDITIONAL REGULATION OF THE HYPOXIA-INDUCIBLE FACTOR-1 BY THE VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN		

REVOCATION OF POWER OF ATTORNEY, GRANT OF NEW POWER OF ATTORNEY, AND CHANGE OF CORRESPONDENCE ADDRESS
(INCLUDES STATEMENT UNDER 37 C.F.R. §3.73(b))

Commissioner for Patents
 P.O. Box 1450
 Alexandria, VA 22313-1450

Dear Sir:

AngioGenetics Sweden AB of Stockholm, Sweden ("Assignee"), organized under the laws of the Sweden, states that it is the current Assignee of the entire right, title, and interest to the above-identified U.S. patent application by virtue of a chain of title as follows:

CERTIFICATE OF MAILING OR TRANSMISSION (37 CFR 1.8(a))

I hereby certify that this correspondence (along with any paper referred to as being attached or enclosed) is being:

deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

transmitted by facsimile on the date shown below to the United States Patent and Trademark Office via facsimile at (571) 273-8300.

Date: 02 July, 2007

Signed: Todd E. Gharabedian

Todd E. Gharabedian, Ph.D.

Our Docket No.: 102912-200
Page 2 of 3

1. From: Lorenz Poellinger
Jorge Ruas
Teresa Pereira
To: Aspera Pharmaceuticals

The document was recorded in the United States Patent and Trademark Office at
Reel: 012335, Frame: 0026.

2. From: Aspera Pharmaceuticals To: AngioGenetics Sweden AB

The document was recorded in the United States Patent and Trademark Office at
Reel: 012481, Frame: 0234.

The undersigned is empowered to sign this statement on behalf of the Assignee.

Assignee hereby revokes all previous powers of attorney or authorization of agent given
in this U.S. patent application.

Assignee hereby appoints the practitioners of Wiggin and Dana LLP, who are identified
by the U.S. Patent & Trademark Office under Customer Number 27267 and to transact all
business in the Patent and Trademark Office connected therewith.

Please address all future written and fax correspondence to Customer Number:

27267


27267

PATENT TRADEMARK OFFICE

Patent Docket Coordinator
WIGGIN and DANA LLP
One Century Tower
P.O. Box 1832
New Haven, CT 06508-1832
Telephone: (203) 498-4400
Facsimile: (203) 782-2889

Our Docket No.: 102912-200
Page 3 of 3

Please direct all phone and email communications to Todd E. Garabedian, Ph.D., Reg. No. 39,197 at Wiggin and Dana LLP, phone: 203-498-4400 and email: tgarabedian@wiggin.com.



Signature of authorized person
for AngioGenetics Sweden AB

By: Mats Hellström

Title: Chief Executive Officer

Date: 7 June, 2007

CONTACT INFORMATION:
WIGGIN and DANA LLP
One Century Tower
New Haven, CT 06508-1832
Telephone: (860) 297-3716
Faxsimile: (203) 782-2889
Email: tgarabedian@wiggin.com

\18516\6\54412.1